All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The QuANTUM-First trial: What is the impact of MRD on the management of patients with FLT3-mutated AML?
Bookmark this article
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak with Alexander Perl, University of Pennsylvania, Philadelphia, US. We asked, The QuANTUM-First trial: What is the impact of MRD on the management of patients with FLT3-mutated acute myeloid leukemia?
The QuANTUM-First trial: What is the impact of MRD on the management of patients with FLT3-mutated AML?
Perl discusses the phase III QuANTUM-First trial (NCT02668653) evaluating the impact of FLT3-internal tandem duplication (ITD) measurable residual disease (MRD) positivity as measured by a highly sensitive polymerase chain reaction-next-generation sequencing assay on long-term survival outcomes, and how quizartinib affects MRD levels vs placebo. He then highlights data from the phase III MORHO trial (NCT02997202) assessing the impact of FLT3-ITD MRD status before allogeneic hematopoietic stem cell transplant on posttransplant survival outcomes. Perl concludes by considering the potential integration of FLT3-ITD MRD measurement into routine clinical practice for risk stratification and to guide treatment options.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox